dichloro-pyrimidin-2-yl-amine | 955997-69-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: dichloro-pyrimidin-2-yl-amine
• 英文别名: Dichloroaminopyrimidine；N,N-dichloropyrimidin-2-amine
• CAS: 955997-69-0
• 化学式: C₄H₃Cl₂N₃
• 分子量: 163.994
• InChiKey: TUIARYVFXLMHBS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  29
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4,6-Dibromo-5-aminopyrimidine 、 dichloro-pyrimidin-2-yl-amine 以gives 5-amino-6-bromo-4-guanidinopyrimidine hydrobromide的产率得到5-Amino-6-bromo-4-guanidinopyrimidine hydrobromide
  参考文献：
  名称：

  Pharmaceutical compositions containing guanidinopyrimidines

  摘要：

  描述了含有某些4-鸟氨基吡啶作为活性利尿成分的药物组合物。代表性利尿化合物是5-氨基-6-氯-4-鸟氨基嘧啶和6-氨基-5-硝基-4-鸟氨基嘧啶。

  公开号：

  US04336255A1

文献信息

• [EN] AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS<br/>[FR] AZOLOPYRIMIDINE POUR LE TRAITEMENT DE TROUBLES LIÉS AU CANCER
  申请人：ARCUS BIOSCIENCES INC

  公开号：WO2018136700A1

  公开（公告）日：2018-07-26

  Compound that is an inhibitor of at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. The use of such compound and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.

  本文描述了一种至少抑制A2A和A2B腺苷受体中至少一种的化合物，以及含有该化合物的组合物和合成该化合物的方法。利用这种化合物和组合物治疗各种疾病、紊乱和病况，包括至少部分由腺苷A2A受体和/或腺苷A2B受体介导的癌症和免疫相关紊乱。
• [EN] CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY<br/>[FR] PYRIDINES CONDENSEES ET PYRIMIDINES A ACTIVITE TIE2 (TEK)
  申请人：ASTRAZENECA AB

  公开号：WO2004013141A1

  公开（公告）日：2004-02-12

  A compound of the Formula (I), wherein A together with the carbon atoms to which it is attached forms a fused 5-membered heteroaryl ring, wherein said heteroaryl ring contains 1 or 2 heteroatoms selected from O, N and S, and wherein the 5-membered ring containing G is linked to the ring formed by A in the meta position to the bridgehead carbon marked # in Formula (I); G is selected from O, S and NR5; Z is selected from N and CR6; Q1 is selected from optionally substituted aryl and heteroaryl, and the substituents R1 to R6 are as defined in the text for use in the production of an anti-angiogenic effect in a warm blooded animal such as man.

  化合物的公式（I），其中A与其连接的碳原子一起形成一个融合的5-成员杂环芳烃环，其中所述的杂环芳烃环包含1个或2个从O、N和S中选择的杂原子，并且包含G的5-成员环与在公式（I）中标记为桥头碳#的A形成的环在间位连接；G从O、S和NR5中选择；Z从N和CR6中选择；Q1从可选择的取代芳基和杂环芳基中选择，取代基R1到R6如文本中所定义，用于在温血动物（如人）中产生抗血管生成作用。
• [EN] SUBSTITUTED TRIAZOLOPYRIMIDINES AS PDE8 INHIBITORS<br/>[FR] TRIAZOLOPYRIMIDINES SUBSTITUÉES COMME INHIBITEURS DE PDE8
  申请人：PFIZER

  公开号：WO2011058478A1

  公开（公告）日：2011-05-19

  Compounds of Formula (I): wherein R1 , R2, R3, R4, and R5 are as defined herein, are disclosed.

  式(I)的化合物：其中R1，R2，R3，R4和R5如本文所定义，已被披露。
• Condensed pyridines and pyrimidines with tie2 (tek) activity
  申请人：Luke Arthur Richard William

  公开号：US20050256140A1

  公开（公告）日：2005-11-17

  A compound of the Formula (I), wherein A together with the carbon atoms to which it is attached forms a fused 5-membered heteroaryl ring, wherein said heteroaryl ring contains 1 or 2 heteroatoms selected from O, N and S, and wherein the 5-membered ring containing G is linked to the ring formed by A in the meta position to the bridgehead carbon marked # in Formula (I): G is selected from O, S and NR 5 ; Z is selected from N and CR 6 ; Q 1 is selected from optionally substituted aryl and heteroaryl, and the substituents R 1 to R 6 are as defined in the text for use in the production of an anti-angiogenic effect in a warm blooded animal such as man.

  化合物的式子（I），其中A与其连接的碳原子一起形成一个融合的5元杂环芳基环，其中该杂环芳基环含有1或2个从O，N和S中选择的杂原子，并且含有G的5元环与在式子（I）中被标记为#的桥头碳上的A形成的环在间位连接：G从O，S和NR5中选择；Z从N和CR6中选择；Q1从可选取代的芳基和杂环基中选择，取代基R1到R6如文本中所定义，用于在温血动物如人中产生抗血管生成效应的制备。
• Thienopyrimidines and Thiazolopyrimidines for Use in Medicine
  申请人：Bower Fairfield Justin

  公开号：US20070244133A1

  公开（公告）日：2007-10-18

  The use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X 1 , X 2 , X 3 , X 4 , R a , p, R 1 , Z, Y, R 2 , R 3 and R 4 are as defined in the specification, in the preparation of a medicament for the treatment of C—C chemokine mediated conditions, such as inflammatory disease. Certain compounds of formula (I) are novel and these, together with their preparation are also described and claimed.

  使用公式（I）或其药学上可接受的盐或溶剂，其中X1，X2，X3，X4，Ra，p，R1，Z，Y，R2，R3和R4如规范所定义，在制备治疗C-C趋化因子介导疾病（如炎症性疾病）的药物中使用。公式（I）的某些化合物是新颖的，这些化合物以及它们的制备也被描述和声明。